Tag:

Takeda

Latest Headlines

Latest Headlines

Takeda places vaccines unit in Singapore to push for global growth

Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.

Takeda's betting on its pipeline to spur a long-awaited turnaround

Japanese giant Takeda Pharmaceutical is planning to finally return to growth next year, counting on its late-stage medicines to the lead charge.

Takeda will grow again in the coming year, COO Weber promises

Takeda's revenues and profits will be down for the second year running. But COO Christophe Weber is promising better things to come. With a reorganization in place and some new drugs in the market and the pipeline, he said investors can expect growth going forward.

Takeda groups emerging markets, vaccines units in Singapore as dengue PhIII ahead

Japan's Takeda Pharmaceutical opened an emerging markets and vaccines headquarters in the gleaming new research hub Biopolis on Feb. 25 in the wealthy city-state as it looks to bring a Phase III dengue candidate through trials successfully and challenge Sanofi's lead in the space.

Takeda makes an M&A move in Turkey

Takeda's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently said he is ready to do some deals to capitalize on those areas, and now he has executed one that straddles two of those favorites.

Takeda's lung cancer drug motesanib fails--again--in Phase III odyssey

Three years after Takeda decided to double down on motesanib for non-small cell lung cancer, in-licensing full rights to the drug from Amgen following their big Phase III failure in 2011, the company has once again come up empty-handed in a major late-stage test of the therapy.

Another Actos lawsuit reaches a jury for weary Takeda

Another jury in another U.S. trial over Takeda Pharmaceutical and its Actos (pioglitazone) diabetes drug has begun deliberating whether the drug was responsible for causing cancer. Lawyers for both sides completed closing arguments in the Pennsylvania trial.

Takeda says its 'breakthrough' cancer drug came through in Phase III

Takeda's top oncology prospect met its main goal in a Phase III trial, the Japanese drugmaker said, paving the path to an FDA submission for a drug the company hopes can succeed its blockbuster Velcade.

Takeda drops DTaP/sIPV development to focus on 'higher-impact' programs

After creating a global specialty unit for its vaccines business and tapping a new development head last fall, Takeda now plans to drop a Phase II Diphtheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV) program in Japan to focus on markets where it can make a bigger splash.

Takeda eyeing vaccinemakers as entry point to India

SINGAPORE-- Takeda Pharmaceutical has identified a handful of Indian vaccinemakers as targets for M&A or other deal structures as it gets ready to take a plunge into a market that saw rival Daiichi Sankyo find nothing but trouble, according to sources that have spoken to executives at the Japanese company.